FOXO4-DRI
Research chemical · Grade C
Goals
longevity, immune
Evidence
0 RCT / 2 animal / 4 in vitro
Routes
injectable-sc
WADA
No
FDA
Not approved
Cancer caution
hard-stop
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.